• Something wrong with this record ?

A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer

S. Novotna, K. Valentova, J. Fricova, E. Richterova, S. Harabisova, F. Bullier, F. Trinquet, . ,

. 2014 ; 36 (3) : 357-67. [pub] 20140205

Language English Country United States

Document type Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2002-01-01 to 2 months ago
Medline Complete (EBSCOhost) from 2012-09-01 to 2015-07-31
Nursing & Allied Health Database (ProQuest) from 2002-01-01 to 2 months ago
Health & Medicine (ProQuest) from 2002-01-01 to 2 months ago
Health Management Database (ProQuest) from 2002-01-01 to 2 months ago

BACKGROUND: Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of fentanyl suprabioavailable to oral transmucosal fentanyl citrate with a higher early systemic exposure and a shorter Tmax. OBJECTIVES: This study evaluated the efficacy and safety profile of fentanyl Ethypharm (FE) in relieving BTP in opioid-treated cancer patients. METHODS: Opioid-treated adult cancer patients, experiencing 1 to 4 episodes of BTP per day, were included in the study. After an open-label titration period to identify an optimal dose that would provide adequate pain relief for 2 consecutive episodes of BTP with an acceptable level of adverse events, patients were randomly assigned to a double-blind, placebo-controlled, crossover period with 1 of 13 prespecified sequences of 9 tablets (6 tablets of FE of the dose identified during the open-label titration and 3 placebo). Pain intensity and pain relief were recorded at 3, 6, 10, 15, 30, and 60 minutes after study drug administration. Adverse events were recorded. The primary end point was the sum of pain intensity differences (SPID) at 30 minutes. RESULTS: The distribution of optimal dosages of FE was as follows: 133 μg, 35.9%; 267 μg, 30.8%; 400 μg, 14.1%; 533 μg, 12.8%; and 800 μg, 6.4%. In the modified intention-to-treat population (n = 73), FE significantly improved mean (SE) SPID compared with placebo at 30 minutes (75.0 [49.8] vs 52.5 [52.8]; P < 0.0001). FE significantly improved SPID, pain intensity difference, and pain relief compared with placebo from 6 to 60 minutes' postadministration. Patients with BTP who received placebo required the use of rescue medication more often than those treated with FE (38.4% vs 17.5%; P < 0.0001). A significant improvement in pain scores (>33% and >50% reductions) was also reported for BTP treated with FE. Pain scores for patients with BTP with a neuropathic component (13 patients) were lower with FE than for those receiving placebo, but the difference was not significant. AEs were of mild or moderate severity and typical of opioid drugs. CONCLUSIONS: This newly developed galenic formulation with a higher early systemic exposure and a shorter Tmax compared with oral transmucosal fentanyl citrate makes FE a particularly suitable formulation for the management of BTP in opioid-treated cancer patients due to the very rapid onset of action. FE provided significant improvement in pain intensity of BTP compared with placebo as early as 6 minutes' postadministration with a sustained effect over 60 minutes. FE was well tolerated by patients. ClinicalTrials.gov identifier: NCT 01842893.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010792
003      
CZ-PrNML
005      
20241024103440.0
007      
ta
008      
160408s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clinthera.2014.01.006 $2 doi
024    7_
$a 10.1016/j.clinthera.2014.01.006 $2 doi
035    __
$a (PubMed)24508417
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Novotna, Stanislava $u Vysokomytska nemocnice, Vysoke Myto.
245    12
$a A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer / $c S. Novotna, K. Valentova, J. Fricova, E. Richterova, S. Harabisova, F. Bullier, F. Trinquet, . ,
520    9_
$a BACKGROUND: Oromucosal fentanyl is currently used for the treatment of breakthrough pain (BTP) in opioid-treated cancer patients. Ethypharm developed a sublingual formulation of fentanyl suprabioavailable to oral transmucosal fentanyl citrate with a higher early systemic exposure and a shorter Tmax. OBJECTIVES: This study evaluated the efficacy and safety profile of fentanyl Ethypharm (FE) in relieving BTP in opioid-treated cancer patients. METHODS: Opioid-treated adult cancer patients, experiencing 1 to 4 episodes of BTP per day, were included in the study. After an open-label titration period to identify an optimal dose that would provide adequate pain relief for 2 consecutive episodes of BTP with an acceptable level of adverse events, patients were randomly assigned to a double-blind, placebo-controlled, crossover period with 1 of 13 prespecified sequences of 9 tablets (6 tablets of FE of the dose identified during the open-label titration and 3 placebo). Pain intensity and pain relief were recorded at 3, 6, 10, 15, 30, and 60 minutes after study drug administration. Adverse events were recorded. The primary end point was the sum of pain intensity differences (SPID) at 30 minutes. RESULTS: The distribution of optimal dosages of FE was as follows: 133 μg, 35.9%; 267 μg, 30.8%; 400 μg, 14.1%; 533 μg, 12.8%; and 800 μg, 6.4%. In the modified intention-to-treat population (n = 73), FE significantly improved mean (SE) SPID compared with placebo at 30 minutes (75.0 [49.8] vs 52.5 [52.8]; P < 0.0001). FE significantly improved SPID, pain intensity difference, and pain relief compared with placebo from 6 to 60 minutes' postadministration. Patients with BTP who received placebo required the use of rescue medication more often than those treated with FE (38.4% vs 17.5%; P < 0.0001). A significant improvement in pain scores (>33% and >50% reductions) was also reported for BTP treated with FE. Pain scores for patients with BTP with a neuropathic component (13 patients) were lower with FE than for those receiving placebo, but the difference was not significant. AEs were of mild or moderate severity and typical of opioid drugs. CONCLUSIONS: This newly developed galenic formulation with a higher early systemic exposure and a shorter Tmax compared with oral transmucosal fentanyl citrate makes FE a particularly suitable formulation for the management of BTP in opioid-treated cancer patients due to the very rapid onset of action. FE provided significant improvement in pain intensity of BTP compared with placebo as early as 6 minutes' postadministration with a sustained effect over 60 minutes. FE was well tolerated by patients. ClinicalTrials.gov identifier: NCT 01842893.
650    _2
$a aplikace sublinguální $7 D000286
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a opioidní analgetika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000701
650    _2
$a průlomová bolest $x farmakoterapie $7 D059390
650    _2
$a klinické křížové studie $7 D018592
650    _2
$a management nemoci $7 D019468
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fentanyl $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005283
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a management bolesti $7 D059408
650    _2
$a měření bolesti $7 D010147
650    _2
$a tablety $7 D013607
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Valentova, Klara $u Nemocnice s poliklinikou v Semilech, Semily.
700    1_
$a Fricová, Jitka, $d 1971- $u Vseobecna fakultni nemocnice, Prague. $7 xx0105524
700    1_
$a Richterova, Eva $u Ambulance lecby chronicke bolesti a paliativni mediciny, Hradec Kralove.
700    1_
$a Harabisova, Sarka $u Metstska nemocnice Ostrava, Ostrava, Czech Republic.
700    1_
$a Bullier, Françoise $u ICTA PM, Fontaine les Dijon, France. Electronic address: trinquet.francoise@ethypharm.com.
700    1_
$a Trinquet, Françoise $u Ethypharm, Saint Cloud, France.
700    1_
$a ,
773    0_
$w MED00001165 $t Clinical therapeutics $x 1879-114X $g Roč. 36, č. 3 (2014), s. 357-67
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24508417 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20241024103434 $b ABA008
999    __
$a ok $b bmc $g 1114221 $s 935160
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 36 $c 3 $d 357-67 $e 20140205 $i 1879-114X $m Clinical therapeutics $n Clin Ther $x MED00001165
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...